Cryoablation for Monomorphic Ventricular Tachycardia (VTS) (FULCRUM-VT)
Cryoablation for Monomorphic Ventricular Tachycardia IDE Study
研究概览
详细说明
A prospective, single-arm, multi-center, open label, pre-market, clinical study designed to provide safety and efficacy data regarding the use of the Adagio System in the treatment of scar-mediated SMVT in ischemic and non-ischemic patients. Study subjects will include patients who experience recurrent SMVT and are scheduled for an endocardial VT ablation. Study subjects must have an Implantable Cardioverter Defibrillator (ICD) prior to the cryoablation procedure.
The VTS study is being initiated to collect safety and effectiveness data and support future PMA supplement marketing application.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Doug Kurschinski
- 邮箱:dkurschinski@adagiomedical.com
研究联系人备份
- 姓名:Nabil Jubran, MS
- 电话号码:207 949 329 2494
- 邮箱:njubran@adagiomedical.com
学习地点
-
-
-
Montreal、加拿大
- 招聘中
- Montreal Hear Institute
-
接触:
- Katia Dydra, MD
-
-
Quebec
-
Montreal、Quebec、加拿大、H3G 1A4
- 招聘中
- McGill University Health Centre (MUHC), Montreal General Hospital (MGH)
-
接触:
- Atul Verma, MD
-
-
-
-
Arizona
-
Phoenix、Arizona、美国、85006
- 招聘中
- Banner University Medical Center Phoenix
-
-
California
-
Long Beach、California、美国、90806
- 招聘中
- MemorialCare Long Beach Medical Center
-
接触:
- Mark Lee, MD
- 电话号码:(562) 933-2000
- 邮箱:markyounglee@gmail.com
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- 招聘中
- Brigham and Women's Hospital
-
-
New York
-
Staten Island、New York、美国、10305
- 招聘中
- Northwell Health- Staten Island University Hospital
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- 招聘中
- Hospital of University of Pennsylvania
-
-
South Carolina
-
Charleston、South Carolina、美国、29403
- 招聘中
- Medical Center of South Carolina (MUSC)
-
-
Tennessee
-
Nashville、Tennessee、美国、37232
- 招聘中
- Vanderbilt University Medical Center
-
-
Virginia
-
Richmond、Virginia、美国、23219
- 招聘中
- Virginia Commonwealth University
-
接触:
- Ajay Pillai, MD
- 邮箱:ajay.pillai@vcuhealth.org
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- IC 1 Male or female ≥ 18 years
- IC 2 Patients with a clinical indication for catheter ablation due to ischemic and/or non-ischemic heart disease and recurrent symptomatic sustained scar-mediated monomorphic Ventricular Tachycardia.
IC 3 Any of the following:
- Ischemic cardiomyopapthy (ICM) patients with prior history of myocardial infarction with Q waves, focal wall motion abnormality on imaging, fixed perfusion defect correlating with coronary stenosis or prior coronary intervention, 20% ≤ LVEF < 50%.
- non-ischemic cardiomyopathy (NICM) patients with scar in a territory without coronary stenosis as evidenced by CMR imaging within the prior 90 days or intra-procedurally using EAM and PES prior to investigational device use, 20% ≤ LVEF < 50%
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- IC 4 Has received a market-released ICD prior to enrollment
- IC 5 Patient has had at least 1 documented spontaneous episode of SMVT within the previous 6 months
- IC 6 Refractory to, or intolerant of, at least one Class III AAD. (Refractory or intolerant defined as AAD failure due to recurrent VT, not tolerated/ desired due to side effects)
- IC 7 Willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study
- IC 8 Willingness and ability to give an informed consent
Exclusion Criteria:
- EC 1 Intracardiac thrombus by TTE or TEE within 48 hours prior to the procedure
- EC 2 Presence of isolated epicardial scar(s) requiring epicardial ablation identified by either preoperative CMR imaging within 90 days of procedure or intra-procedurally using EAM and PES prior to investigational device use
EC 3 VTs due to any of the following causes:
- Idiopathic VT
- Automaticity or triggered activity
- Bundle Branch Reentry (BBR)
- Any focal tachycardia (e.g., papillary, RVOT)
- Ventricular tachycardia secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause
EC 4 NICM patients only, if any of the following apply:
- Congenital condition that limits access to the left or right ventricles
- Severe aortic or mitral stenosis, severe mitral regurgitation, or severe aortic insufficiency
- Active inflammatory processes (e.g., myocarditis) within the past 120 days
- Sarcoidosis
- Hypertrophic cardiomyopathy
- Drug- or alcohol-induced cardiomyopathy
- EC 5 Any VT ablation within 4 weeks prior to enrollment
- EC 6 More than one prior (>4 weeks) VT ablation or prior surgical treatment for VT within the past 2 years
- EC 7 Cardiogenic shock, unless it is due to incessant monomorphic VT
EC 8 Any other cardiovascular conditions as described below:
- Class IV heart failure
- Aortic aneurysm
- Previous cardiac surgery or percutaneous coronary intervention within 60 days prior to index procedure
- Interatrial baffle, closure device, patch, or PFO occlusion device
- Coronary artery bypass graft (CABG) procedure within six (6) months prior to the ablation procedure
- Acute MI or unstable angina in the previous 60 days
- Mechanical mitral or aortic valve
- Cardiac myxoma
- Significant congenital heart disease
- EC 9 Acute illness or active systemic infection
- EC 10 Any previous history of cryoglobulinemia
- EC 11 History of blood clotting or bleeding disease
- EC 12 Peripheral vascular disease that precludes LV access
- EC 13 Contraindication to heparin
- EC 14 Allergy to radiographic contrast dye that cannot be medically managed prior to the ablation procedure
- EC 15 Any prior history of documented cerebral vascular accident (CVA), TIA or systemic embolism (excluding a post-operative Deep Vein Thrombosis, DVT), within 6 months prior to the ablation procedure.
- EC 16 Pregnant, or anticipated pregnancy during study follow-up
- EC 17 Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study
- EC 18 Any other condition (e.g., ARVC with extensive free wall scarring) that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, candidate for heart transplantation, patient with ventricular assist device, or terminal illness with a life expectancy less than 12 months)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:VT Cryoablation
all enrolled patients will have a ablation procedure using the vCLAS Ventricular Ablation System (VTS Catheter and Console) for SMVT
|
ablation procedure using the investigational device (vCLAS Ventricular Ablation System including VTS Catheter and Console)
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Primary Safety Endpoint - Freedom from definite or probable device or procedure related Major Adverse Events (MAEs) that occur within 7 days following the ablation procedure.
大体时间:7 days following the ablation procedure
|
Primary Safety Endpoint is freedom from definite or probable device or procedure related Major Adverse Events (MAEs) that occur within 7 days following the ablation procedure. Events will be adjudicated by an independent Clinical Events Committee (CEC). MAEs include any of the following: • Death • Acute myocardial infarction • Cardiac perforation/pericardial tamponade • Cerebral infarct or systemic embolism • Major bleeding requiring transfusion • Acute Mitral, Tricuspid or Aortic valve damage resulting in moderate or severe regurgitation • Access site complications requiring medical or surgical intervention • Pericarditis • Heart block requiring a permanent pacemaker • Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent Clinical Events Committee (CEC) to be probably or definitely related to the Adagio System. |
7 days following the ablation procedure
|
|
Primary Efficacy Endpoint - Freedom from recurrent sustained MMVT in the absence of a new AAD or increase in dose of a pre-ablation AAD for VT management at 6 months following the ablation procedure
大体时间:6 months after the procedure
|
Primary Efficacy Endpoint is defined as freedom from recurrent sustained MMVT in the absence of a new AAD or increase in dose of a pre-ablation AAD for VT management at 6 months following the ablation procedure, where sustained MMVT is defined as continuous MMVT for > 30 seconds (programmed monitoring zone only), or MMVT requiring appropriate ICD intervention regardless of duration.
All ICD interrogation reports will be adjudicated by an independent VT Event Committee (VTEC) to support the primary efficacy endpoint.
|
6 months after the procedure
|
|
Primary Procedural Endpoint - Percentage of non-inducibility VT targeted for ablation post-procedure
大体时间:at the end of the ablation procedure
|
Primary Procedural Endpoint is defined as non-inducibility of any VT targeted for ablation at the end of the procedure
|
at the end of the ablation procedure
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Secondary Safety Endpoint - Freedom from definite or probable device or procedure related Serious Adverse Events (SAEs) within 12 months following the ablation procedure
大体时间:12-months post ablation procedure
|
Secondary Safety Endpoint is defined as freedom from definite or probable device or procedure related Serious Adverse Events (SAEs) within 12 months following the ablation procedure.
Events will be adjudicated by an independent Clinical Events Committee (CEC).
|
12-months post ablation procedure
|
|
Secondary Efficacy Endpoint - Freedom from VT greater than 30 seconds or appropriate ICD intervention at 12 months
大体时间:12-months post ablation procedure
|
Secondary Efficacy Endpoint is defined as freedom from Ventricular Tachycardia lasting longer than 30 seconds or appropriate ICD intervention at 12 months
|
12-months post ablation procedure
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.